Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Orlistat

A Proof of Concept Trial in Overweight and Obese Patients, Investigating Effect of EMP16-02 on Body Weight (Primary)

Empros Pharma AB · Phase 1/2 · Completed · Enrollment 156

NCT04521751

ArmPopulationDoseWeeksEstimandWeight change
EMP16-02 120 mg orlistat/40 mg acarboseObesity or overweight40 mg26n/rn/r
EMP16-02 150 mg orlistat/50 mg acarboseObesity or overweight50 mg26n/rn/r
PlaceboObesity or overweightn/r26n/rn/r